Molecular Forecaster Participates in the $165-million CFREF grant awarded to McGill University to support its inclusive genomics and RNA research program

As a McGill University spinout company, we at Molecular Forecaster are thrilled to support the recent landmark government investment into our alma mater through “DNA to RNA: An Inclusive Canadian Approach to Genomic-based RNA Therapeutics (D2R)”. The $165M investment, bolstered by another $185M+ commitment from academic and industrial partners will go towards supporting fundamental RNA research, including drug discovery efforts, which aligns perfectly with our company's mission and values.

$165-million for McGill University’s world-leading inclusive genomics and RNA research program

McGill is the recipient of a landmark $165 million CFREF grant to launch DNA to RNA: An Inclusive Canadian Approach to Genomic-based RNA Therapeutics (D2R), a first-of-its-kind global research effort specializing in the development and delivery of more inclusive genomic-based RNA therapeutics. D2R will receive significant support from more than 50 partners, including many from academia and industry, who have all pledged to invest in the research, which brings the total amount invested in D2R to $353 million.

NewsGuest UserMay 8, 2023BIOOQuébecMcGill University, genomic therapy, RNA technology

Laurent Pharmaceuticals Joins Battle Against COVID-19

Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company that spun off from McGill University in 2012, today announces that it is planning to test its lead drug LAU-7b in patients with COVID-19 disease, as part of a Phase 2 clinical trial.